Oppenheimer analyst Hartaj Singh downgraded Alexion Pharmaceuticals (ALXN) to Hold today. The company’s shares closed last Monday at $75.56, close to its 52-week low of $72.67.
According to TipRanks.com, Singh is a 2-star analyst with an average return of -0.4% and a 39.8% success rate. Singh covers the Healthcare sector, focusing on stocks such as Catabasis Pharmaceuticals, Vertex Pharmaceuticals, and Strongbridge Biopharma.
Alexion Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $140.64, which is a 90.9% upside from current levels. In a report issued on March 5, Merrill Lynch also downgraded the stock to Hold with a $110.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $141.86 and a one-year low of $72.67. Currently, Alexion Pharmaceuticals has an average volume of 2.24M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its products include ultomiris, soliris, strensiq and kanuma. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P.
